Title: A Study of the Feasibility of FDG-PET/CT to Systematically Detect and Quantify Differential Metabolic Effects of Chronic Tobacco Use in Organs of the Whole Body-A Prospective Pilot Study.
Authors: Torigian, Drew A; Green-McKenzie, Judith; Liu, Xianling; Shofer, Frances S; Werner, Thomas; Smith, Catherine E; Strasser, Andrew A; Moghbel, Mateen C; Parekh, Ami H; Choi, Grace; Goncalves, Marcus D; Spaccarelli, Natalie; Gholami, Saied; Kumar, Prithvi S; Tong, Yubing; Udupa, Jayaram K; Mesaros, Clementina; Alavi, Abass
Published In Acad Radiol, (2017 08)
Abstract: The aim of this study was to assess the feasibility of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to systematically detect and quantify differential effects of chronic tobacco use in organs of the whole body.Twenty healthy male subjects (10 nonsmokers and 10 chronic heavy smokers) were enrolled. Subjects underwent whole-body FDG-PET/CT, diagnostic unenhanced chest CT, mini-mental state examination, urine testing for oxidative stress, and serum testing. The organs of interest (thyroid, skin, skeletal muscle, aorta, heart, lung, adipose tissue, liver, spleen, brain, lumbar spinal bone marrow, and testis) were analyzed on FDG-PET/CT images to determine their metabolic activities using standardized uptake value (SUV) or metabolic volumetric product (MVP). Measurements were compared between subject groups using two-sample t tests or Wilcoxon rank-sum tests as determined by tests for normality. Correlational analyses were also performed.FDG-PET/CT revealed significantly decreased metabolic activity of lumbar spinal bone marrow (MVPmean: 29.8 ± 9.7 cc vs 40.8 ± 11.6 cc, P = 0.03) and liver (SUVmean: 1.8 ± 0.2 vs 2.0 ± 0.2, P = 0.049) and increased metabolic activity of visceral adipose tissue (SUVmean: 0.35 ± 0.10 vs 0.26 ± 0.06, P = 0.02) in chronic smokers compared to nonsmokers. Normalized visceral adipose tissue volume was also significantly decreased (P = 0.04) in chronic smokers. There were no statistically significant differences in the metabolic activity of other assessed organs.Subclinical organ effects of chronic tobacco use are detectable and quantifiable on FDG-PET/CT. FDG-PET/CT may, therefore, play a major role in the study of systemic toxic effects of tobacco use in organs of the whole body for clinical or research purposes.
PubMed ID: 27769824
MeSH Terms: Adult; Aorta/diagnostic imaging; Aorta/metabolism; Bone Marrow/diagnostic imaging; Bone Marrow/metabolism; Brain/diagnostic imaging; Brain/metabolism; Case-Control Studies; Cigarette Smoking/metabolism*; Feasibility Studies; Fluorodeoxyglucose F18; Heart/diagnostic imaging; Humans; Intra-Abdominal Fat/diagnostic imaging; Intra-Abdominal Fat/metabolism; Liver/diagnostic imaging; Liver/metabolism; Lung/diagnostic imaging; Lung/metabolism; Male; Middle Aged; Muscle, Skeletal/diagnostic imaging; Muscle, Skeletal/metabolism; Myocardium/metabolism; Pilot Projects; Positron Emission Tomography Computed Tomography*; Prospective Studies; Radiopharmaceuticals; Skin/diagnostic imaging; Skin/metabolism; Spleen/diagnostic imaging; Spleen/metabolism; Testis/diagnostic imaging; Testis/metabolism; Thyroid Gland/diagnostic imaging; Thyroid Gland/metabolism